Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer
出版年份 2014 全文链接
标题
Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer
作者
关键词
-
出版物
JNCI-Journal of the National Cancer Institute
Volume 106, Issue 1, Pages -
出版商
Oxford University Press (OUP)
发表日期
2014-01-09
DOI
10.1093/jnci/djt335
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
- (2012) A F Munro et al. BRITISH JOURNAL OF CANCER
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
- (2012) T. Popova et al. CANCER RESEARCH
- Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry
- (2012) A. M. Mulligan et al. CLINICAL CANCER RESEARCH
- Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis
- (2012) Michail Ignatiadis et al. JOURNAL OF CLINICAL ONCOLOGY
- Importance of PIKKs in NF-κB activation by genotoxic stress
- (2011) Hélène Sabatel et al. BIOCHEMICAL PHARMACOLOGY
- Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue
- (2011) Richard D. Kennedy et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
- (2011) Angelo Di Leo et al. LANCET ONCOLOGY
- Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without G-CSF in Locally Advanced Breast Cancer: Long-Term Results
- (2011) B. K. Arun et al. ONCOLOGIST
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
- (2010) Stephen B. Edge et al. ANNALS OF SURGICAL ONCOLOGY
- DNA repair signature is associated with anthracycline response in triple negative breast cancer patients
- (2010) A. A. Rodriguez et al. BREAST CANCER RESEARCH AND TREATMENT
- Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer
- (2010) A. Tabchy et al. CLINICAL CANCER RESEARCH
- BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications
- (2010) Rebecca J. Linger et al. FEBS Journal
- Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer
- (2010) Takayuki Iwamoto et al. JNCI-Journal of the National Cancer Institute
- Susceptibility Pathways in Fanconi's Anemia and Breast Cancer
- (2010) Alan D. D'Andrea NEW ENGLAND JOURNAL OF MEDICINE
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- TLR8-dependent TNF- overexpression in Fanconi anemia group C cells
- (2009) S. M. Vanderwerf et al. BLOOD
- Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer inBRCA1andBRCA2Mutation Carriers
- (2009) Mieke Kriege et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
- (2009) R. M. Simon et al. JNCI-Journal of the National Cancer Institute
- The FANC pathway and BLM collaborate during mitosis to prevent micro-nucleation and chromosome abnormalities
- (2009) Valeria Naim et al. NATURE CELL BIOLOGY
- Generation of a non-small cell lung cancer transcriptome microarray
- (2008) Austin Tanney et al. BMC Medical Genomics
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started